Results 191 to 200 of about 63,819 (300)

Hazelnut and Walnut Vicilins in Tree Nut Allergy: Co‐Sensitization Patterns and Clinical Severity Associations

open access: yesAllergy, EarlyView.
This observational analysis of a consecutive tertiary‐care cohort included 70 patients with walnut allergy and 44 patients with hazelnut allergy. Clinical severity was classified as mild, moderate, or severe. Hazelnut and walnut allergy severity was better captured by molecule‐specific IgE profiles than by undifferentiated seed storage protein ...
Danilo Villalta   +14 more
wiley   +1 more source

Evaluation of the clinical utility of medical tests in chronic urticaria. [PDF]

open access: yesJ Allergy Clin Immunol Glob
Sánchez J, Caraballo AL, García E.
europepmc   +1 more source

Factors for Success and Failure of Allergen Immunotherapy (AIT) Trial Design in the Light of Evidence‐Based Medicine: Current Aspects 2026

open access: yesAllergy, EarlyView.
ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk   +10 more
wiley   +1 more source

Dermographometer assessment in children with urticaria. [PDF]

open access: yesWorld Allergy Organ J
Suksai P   +5 more
europepmc   +1 more source

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

open access: yesAllergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov   +43 more
wiley   +1 more source

Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial

open access: yesAllergy, EarlyView.
This study reports exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count and FeNO levels. In adults with moderate‐to‐severe uncontrolled asthma, rademikibart produced rapid and sustained improvements in lung function and asthma control.
Michael E. Wechsler   +3 more
wiley   +1 more source

The role of Infections in Urticaria

open access: yes, 2003
D   +5 more
core  

Home - About - Disclaimer - Privacy